Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 Earnings

BioMarin Pharmaceutical (BMRN) reported $646.21 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 20.2$0.49 for the same period compares to $0.36 a year ago.The reported revenue compares to the Zacks Consensus Estimate of$636.71 million, representing a surprise of +1.49%. The company delivered an EPS surprise of +11.36%, with the consensus EPS estimate being $0.44.While investors scrutinize revenue and earnings changes year-over-year and how they co ...